Therapeutic Blood-Acid-Shifting Compositions for Reduced Infusion Volume
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing acid-shifting therapies do not optimize drug volume, particularly in formulations involving pharmaceutical grade acids and pH buffering agents.
Innovation Solution
The use of intravenous buffer solutions comprising pharmaceutical grade acids with therapeutic conjugate bases having a pKa < 3.0, in combination with pharmaceutical grade pH buffering agents, to achieve a therapeutically effective acid shift while minimizing drug volume.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional acid-shifting therapies use pharmaceutical grade acids with pH buffering agents, then acid-shifting therapeutic effect is achieved, but drug volume is not optimized and may cause excessive volume administration
Solution Approach 1:
The patent changes the chemical parameters of the acid-shifting composition by selecting specific pharmaceutical grade acids with defined pKa values (less than 3.0) and optimizing the ratio of acid to buffering agent. This parameter optimization allows achieving the desired acid-shifting effect with reduced total drug volume, resolving the contradiction between volume reduction and therapeutic effectiveness.
Solution Approach 2:
The patent creates a composite acid-shifting composition by combining pharmaceutical grade acids with specific pKa values and pH buffering agents in optimized ratios. This composite formulation achieves enhanced acid-shifting efficiency while minimizing the total volume required, as the synergistic interaction between components produces greater therapeutic effect per unit volume than individual components alone.
2Reliability
If acid-shifting therapy reduces bloodstream pH significantly, then therapeutic benefit is achieved, but vascular irritation and tissue damage risk increases
Solution Approach 1:
The patent introduces pH buffering agents as intermediary substances that mediate between the strong acid and the bloodstream. These buffering agents gradually neutralize the acid, controlling the rate and extent of pH reduction. This intermediary mechanism allows achieving significant therapeutic acid-shifting effect while preventing abrupt, harmful pH changes that would cause vascular irritation and tissue damage.
Solution Approach 2:
The patent employs periodic or controlled administration of the acid-shifting composition rather than continuous or single-dose administration. The buffering agents facilitate controlled, progressive pH reduction over time, allowing the body to adapt gradually. This periodic action pattern achieves cumulative therapeutic benefit while distributing the harmful acid load over time, preventing acute vascular irritation.
3Volume of stationary object
If conventional formulations use standard pH buffering agents, then compatibility with intravenous infusion is maintained, but package volume and infused volume are excessive
Solution Approach 1:
The patent optimizes the concentration parameters and pH values of both the acid and buffering agent to create a formulation that achieves maximum acid-shifting effect per unit volume. By carefully controlling these parameters, the formulation maintains compatibility with intravenous infusion systems while minimizing the total volume required, as the optimized parameters allow more efficient use of each milliliter administered.
Solution Approach 2:
The patent designs a universal acid-shifting composition formulation that simultaneously achieves multiple objectives: effective acid-shifting therapy, controlled pH reduction, minimized volume, and intravenous compatibility. The buffering agents are selected to serve multiple functions - neutralizing acid, controlling pH trajectory, and maintaining solution compatibility - thereby reducing the need for additional separate components and minimizing total package volume.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for efficient acid shifting with reduced physiological bloodstream pH, achieving therapeutic benefits such as improved metabolic acid production management and enhanced oxygen delivery.
Implementation Method 1
pharmaceutical grade acids with therapeutic conjugate bases having a pKa < 3.0
Implementation Method 2
pharmaceutical grade pH buffering agents
Data Source
AI summary
A composition for intravenous injection into an individual's body tissue includes an acid with a pKa less than 3.0 and a conjugate base with therapeutically beneficial properties. The composition has utility in a method of shifting blood-acid for various therapeutic purposes.